Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin‐Deficient Hearts

BACKGROUND: Cardiomyopathy is a leading cause of mortality among Duchenne muscular dystrophy patients and lacks effective therapies. Phosphodiesterase type 5 is implicated in dystrophic pathology, and the phosphodiesterase type 5 inhibitor tadalafil has recently been studied in a clinical trial for...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammers, David W., Sleeper, Margaret M., Forbes, Sean C., Shima, Ai, Walter, Glenn A., Sweeney, H. Lee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015305/
https://www.ncbi.nlm.nih.gov/pubmed/27506543
http://dx.doi.org/10.1161/JAHA.116.003911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015305/
https://www.ncbi.nlm.nih.gov/pubmed/27506543
http://dx.doi.org/10.1161/JAHA.116.003911

Ejemplares similares